Claritev (CTEV) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
20 Mar, 2026Executive summary
Definitive additional proxy materials filed regarding upcoming shareholder meeting.
No filing fee required for this submission, as indicated in the materials.
Voting matters and shareholder proposals
Materials relate to solicitation of proxies for voting at the annual meeting.
Shareholder rights and capital structure
Proxy materials filed to inform shareholders of their rights and voting procedures.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Claritev
- Q1 2026 revenue grew 5.8% to $244.7M, with margin gains but continued net losses.CTEV
Q1 20267 May 2026 - All proposals, including director elections and plan amendments, were approved without contest.CTEVAGM 202629 Apr 2026
- 2026 guidance targets $980M–$1B revenue, 61–62% EBITDA margin, and AI-driven growth.CTEVInvestor Day 202629 Apr 2026
- Board recommends all proxy proposals amid strong 2025 results and governance enhancements.CTEVProxy filing20 Mar 2026
- Record bookings, robust AI-driven growth, and disciplined investment fuel expansion.CTEVStatus update6 Mar 2026
- Revenue and EBITDA grew, losses narrowed, and 2026 outlook includes buybacks and expansion.CTEVQ4 202523 Feb 2026
- Q2 2024 net loss was $576.7M on $233.5M revenue, driven by a $553.7M impairment.CTEVQ2 20242 Feb 2026
- Q3 2024 net loss surged on a $361.6M impairment as revenue fell 5.1% year-over-year.CTEVQ3 202416 Jan 2026
- Transformation, tech investment, and data-driven strategy fuel growth and innovation in healthcare.CTEV44th Annual J.P. Morgan Healthcare Conference15 Jan 2026